Acompanhe as Notícias da Recifes

A new form of CAR T-cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, according to new research led by UCL and Univers

Cancer cells are quick to develop resistance to anti-tumor drugs. New research by scientists from the University of California, Davis, shows how cancers adapt to evade a class of anti-tumor drugs called BET inhibitors and offers hope for more effective therapies.

A new study by researchers at The University of Texas MD Anderson Cancer Center has identified genetic factors that determine whether prostate cancers are susceptible to a type of cell death known as ferroptosis. These findings, published in Nature Communications, could help guid

Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute and Heidelberg University Hospital (UKHD) have developed "HemaGuide," an AI assistant that supports physicians in making difficult treatment decisions. In extensive testing, the system has

A blood test may help identify which patients with colorectal cancer that has spread to the liver are most likely to benefit from chemotherapy after surgery, according to research presented today at the ESMO Gastrointestinal Cancers Congress 2026.

An international research team co-led by the Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC-CSIC-University of Cantabria) and CIC bioGUNE, member of BRTA, has identified a novel molecular mechanism that helps limit the progression of several types of cancer.

Researchers at the University of Pittsburgh, UPMC Hillman Cancer Center and the National Cancer Institute report that combining CAR T cell immunotherapy with a targeted radiopharmaceutical significantly improved tumor regression in preclinical models of neuroblastoma, a rare and

For decades, cancer has been thought of as a purely human disease—rogue cells multiplying out of control, with no room for anything else in the picture. But a growing body of research suggests that isn't quite right. Some tumors, it turns out, come with company: communities of ba

Breast cancers diagnosed during the first three years after childbirth, particularly within the first year, may be biologically more aggressive than similar cancers in women who have never given birth, according to a new study led by investigators at the UCLA Health Jonsson Compr

Glioblastoma, the most aggressive malignant brain tumor in adults, remains one of the most challenging cancers to treat because of limited treatment options and a poor prognosis. Patient outcomes have remained largely unchanged in the past two decades, underscoring the need for i

The epigenetic modifier MLL4 has an unassuming name—the 4, for instance, indicates it's just one in a family of such modifiers. But MLL4 is quite special: In a specific type of leukemia, it drives disease progression, while in solid tumors, it acts as a suppressor.

A healthy bone marrow (BM) produces nearly all types of cells in our blood. Many blood disorders occur when hematopoietic stem cells (HSCs) in the BM malfunction. Treatment with radiation or chemotherapy for many blood disorders and cancers can, as a side effect, deplete not only